Ipilimumab or the gp100 Vaccine or the Combination of Both as Therapy for Patients with Metastatic Melanoma
Ipilimumab or the gp100 Vaccine or the Combination of Both as Therapy for Patients with Metastatic Melanoma
Slides from a presentation at ASCO 2010 and transcribed comments from recent interviews with Jedd D Wolchok, MD, PhD (6/16/10), Steven J O’Day, MD (6/25/10) and David F McDermott, MD (6/25/10)
O’Day S et al. A Phase III randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. Proc ASCO 2010;Abstract 4. Hodi FS et al. Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma. Proc ASCO 2010;Abstract 8509. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;[Epub ahead of print]. Abstract |
||||||||